| 15.18 -0.89 (-5.54%) | 07-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 23.21 | 1-year : | 33.4 |
| Resists | First : | 19.87 | Second : | 28.6 |
| Pivot price | 14.5  |
|||
| Supports | First : | 5.76 | Second : | 4.79 |
| MAs | MA(5) : | 20.43 |
MA(20) : | 12.37 |
| MA(100) : | 7.28 |
MA(250) : | 7.16 |
|
| MACD | MACD : | 3.3 |
Signal : | 2.9 |
| %K %D | K(14,3) : | 47.3 |
D(3) : | 61.9 |
| RSI | RSI(14): 54.2 |
|||
| 52-week | High : | 28.6 | Low : | 1.3 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ARTL ] has closed below upper band by 47.3%. Bollinger Bands are 599.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 11 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 16.99 - 17.11 | 17.11 - 17.2 |
| Low: | 14.78 - 14.92 | 14.92 - 15.04 |
| Close: | 14.98 - 15.18 | 15.18 - 15.33 |
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
Fri, 11 Jul 2025
Artelo Biosciences Plans to Offer 920K Shares of Common Stock - AInvest
Wed, 09 Jul 2025
Artelo Biosciences Soars 30.5% on Promising Depression Drug Data - AInvest
Wed, 09 Jul 2025
Artelo Biosciences’ ART12.11 Shows Promising Antidepressant Effects in Preclinical Study - Yahoo Finance
Mon, 07 Jul 2025
Dow Dips 1%; Mustang Bio Shares Spike Higher - Benzinga
Mon, 07 Jul 2025
Artelo Biosciences Stock Soars On Strong Preclinical Data In Par With Zoloft For Experimental Depression Drug - Stocktwits
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 1 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 0.8 (%) |
| Held by Institutions | 2.6 (%) |
| Shares Short | 12 (K) |
| Shares Short P.Month | 57 (K) |
| EPS | -17.95 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.19 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -89.3 % |
| Return on Equity (ttm) | -190.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -0.85 |
| PEG Ratio | 0 |
| Price to Book value | 12.75 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.19 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|